Without the presence of TILs within the tumor, immune checkpoint inhibition therapies—such as PD1 and PD-L1 inhibitors—cannot effectively block the immune-suppressive signals that allow cancer cells to evade the immune response. Here, CD274 is linked to neoplasm.